FDA approval summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy

Oncologist

Volumn 21, Issue 5, 2016, Pages 634-642

  Kazandjian, Dickran ^a   Suzman, Daniel L ^a   Blumenthal, Gideon ^a   Mushti, Sirisha ^a   He, Kun ^a   Libeg, Meredith ^a   Keegan, Patricia ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Immunotherapy; Nivolumab; Non small cell lung carcinoma; PD 1 inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CREATININE; DOCETAXEL; NIVOLUMAB; PLATINUM; THYROTROPIN; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TAXOID;

ADULT; AGED; ARTICLE; CANCER GROWTH; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DRUG APPROVAL; FATIGUE; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPONATREMIA; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PARANEOPLASTIC NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE COURSE; LUNG NEOPLASMS; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG APPROVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGRAMMED CELL DEATH 1 RECEPTOR; TAXOIDS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84966405086     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0507     Document Type: Article

References (21)

1. National Cancer Institute. SEER stat fact sheets: Lung and bronchus cancer. Available at http://seer.cancer.gov/statfacts/html/lungb.html. Accessed October 15, 2015.
2. Herbst RS, Gandara DR, Hirsch FR et al. Lung master protocol (Lung-MAP)-a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S 1400. Clin Cancer Res 2015;21:1514–1524.
3. Schiller JH, Gandara DR, Goss GD et al. Nonsmall- cell lung cancer: Then and now. J Clin Oncol 2013;31:981–983.
4. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095–2103.
5. Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124–128.
6. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589–1597.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123–132.
8. Oxnard GR, Binder A, Jänne PA. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 2013;31:1097–1104.
9. Davies M. New modalities of cancer treatment for NSCLC: Focus on immunotherapy. Cancer Manag Res 2014;6:63–75.
10. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med 2015; 373:123–135.
11. Kazandjian D, Khozin S, Blumenthal G et al. Benefit-risk summary of nivolumab for patients with metastatic squamous cell lung cancer after platinum-based chemotherapy: A report from the US Food and Drug Administration. JAMA Oncol 2016;2:118–122.
12. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl JMed 2015;372:2018–2028.
13. Merck Sharp & Dohme Corp. Keytruda [package insert]. 2015. Available at http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid59333c79bd487-4538-a9f0-71b91a02b287. Accessed October 27, 2015.
14. Herbst RS, Baas P, Kim D-W et al. Pembrolizumab versus docetaxel for previously treated, PDL1- positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet [Epub ahead of print].
15. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non–smallcell lung cancer. N Engl J Med 2015;373:1627–1639.
16. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med 2012;366:2443–2454.
17. Brahmer JR, Horn L, Antonia SJ et al. Survivaland long-term follow-up of the phase I trial of nivolumab (Anti-PD-1;BMS-936558;ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2013;31(suppl):8030a.
18. Topalian SL, Sznol M, Brahmer JR et al. Nivolumab (anti-PD-1; BMS-936558;ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial. J Clin Oncol 2013;31(suppl): 3002a.
19. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69–74.
20. Snyder A, Makarov V, Merghoub T et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl JMed 2014;371:2189–2199.
21. American Association for Cancer Research. Complexities in personalized medicine: Harmonizing companion diagnostics across a class of targeted therapies. 2015. Available at http://www.aacr.org/ADVOCACYPOLICY/GOVERNMENTAFFAIRS/PAGES/COMPLEXITIES-IN-PERSONALIZED-MEDICINE.ASPX. Accessed December 3, 2015.